Hematopoietic cell transplantation (HCT) is broadly underutilized, [1] [2] [3] particularly in myelodysplastic syndromes (MDS), for which it is the only curative option. Surveys show that HCT is considered in o 4% of patients with MDS in the United States. 4 Older patient age, comorbidities and lack of appropriate donors are often cited as factors contributing to the limited application of HCT in MDS. However, favorable results achieved with non-myeloablative or reduced-intensity regimens and alternative donors in both younger and older patients with MDS 5, 6 negate this logic.
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Since MDS occurs mostly in older patients (median age at diagnosis of at least 65 years of age 7 ) clinicians may question the extent to which a curative procedure will extend life in elderly patients; however, in many countries an individual 65 years of age currently has a life expectancy in excess of 20 additional years. 8 Further, while quality of life (QOL) is a commonly stated concern, the study by El-Jawahri et al. 9 in this issue of Bone Marrow Transplantation demonstrates that baseline patient-reported QOL among older patients with advanced MDS does not influence the decision to undergo HCT. In the context of the traditionally passive role that approximately half of the patients favor in MDS 10 these data reveal that the patient's QOL is not foremost in the decisionmaking process of many clinicians.
Even more disconcerting but compelling explanations for the underutilization of HCT in MDS are survey results showing that patients with MDS often perceive that palliative drugs (for example, azacitidine) can cure their disease, 11 and that many patients and physicians are unaware that HCT can cure MDS. 12 Furthermore, the quality of care of MDS patients is often suboptimal (particularly at low-volume centers 13 ), and limitations of insurance coverage deter many elderly patients from pursuing curative HCT.
14 Decision analyses, reported initially for patients 18-60 years of age 15 and more recently for those 60-70 years, 16 favor early myeloablative and reduced-intensity transplantation, respectively, over non-transplant approaches, to maximize survival in MDS patients with higher risk disease (Intermediate-2 or High risk), as defined by the International Prognostic Scoring System (IPSS). These analyses favor non-transplant approaches in those with lower risk disease. Often 'lost in translation' in these analyses, however, is their design to determine the optimal timing of HCT, not whether transplantation should be performed at all. Similarly, a recent retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) study identified adverse risk factors -including monosomal karyotype and age ⩾ 50-for survival in MDS patients undergoing HCT, but did not address the outcomes of higher-risk MDS patients receiving treatments other than HCT. 17 Notably, while HCT in the decision analyses was restricted to patients with HLA-identical donors, virtually all patients now have a donor for HCT. 18 The initial decision analysis 15 suggests delaying transplantation in lower-risk patients until the evolution of a new cytogenetic abnormality, a clinically important cytopenia or progression to a higher-risk group. In patients 460 years old, no impact of interval from diagnosis to transplantation on survival was identified, suggesting that HCT at the time of disease progression may be a reasonable strategy to extend survival in lower-risk patients. Even in patients who fail azacitidine, HCT is associated with a better outcome than non-transplant therapies. 19 Clearly then, a significant portion of patients ⩽ 70 years of age should be considered for early HCT; in many of the remaining patients, transplantation should be delayed, not disregarded. Select patients in their 70s should also be considered for transplantation as outcomes reported using reduced-intensity regimens appear similar to those for younger patients. 5, 6, 16, 20 While the decision analyses support the use of transplantation in MDS more commonly than is presently applied, they still underestimate both the frequency with which HCT is indicated and the effectiveness of HCT.
The efficacy of HCT for MDS is likely to be significantly underestimated. Based on data demonstrating better outcomes in patients with fewer blasts, 17, 21 many patients now receive hypomethylating agents with improvement in their blast count and IPSS risk group. MDS severity is therefore underestimated in patients responding to salvage therapy prior to transplant, since the decision analyses and other studies routinely categorize IPSS risk by pre-transplant score. Furthermore, in the decision analyses the modeling used assumes no survival beyond 10 years, 15, 16 and therefore fails to capture long-term survivors in the transplant group, of which there were many more compared to the non-transplant cohort.
Underestimation of how often HCT is indicated occurs primarily because the IPSS often underestimates risk, particularly in patients with high-risk genetic features. Newer proposed systems, including the revised IPSS (IPSS-R), improve accuracy 22 by using additional factors to identify those IPSS low-and intermediaterisk patients who are likely to have poor survival. Neither the IPSS nor the IPSS-R recognize mutations, for example, TP53, ASXL1, DNMT3A, EZH2 and RUNX, which are independently associated with adverse outcomes. 23 Moreover, the evolution of cytogenetic and molecular changes, although often not routinely analyzed, may be important in timely identification of the development of high-risk disease. 24 Failure to consider molecular abnormalities associated with poor outcomes overestimates the prognosis in patients with adverse-risk mutations using non-transplant approaches and fails to identify the urgency of HCT in a significant proportion of patients.
Reimbursement has presented an additional obstacle to HCT in older patients.
14 Despite routine coverage of HCT in older patients with AML and evidence of the efficacy of transplant in MDS, including in elderly patients, 5, 6, 16, 20 the Center for Medicare and Medicaid Services (CMS) has had no national policy regarding HCT in MDS, impeding hospitals in the United States from providing this service.
In 2010, CMS initiated coverage with evidence development so that Medicare now covers HCT for patients with MDS participating in an approved clinical study. The Bone Marrow Transplant Clinical Trials Network study 1102, comparing reduced-intensity HCT to non-transplant therapy in patients 50-75 years of age with intermediate-2 and high-risk MDS, 25 represents a qualifying study. This initiative has been critical in improving access to transplant for elderly patients, and data now suggest a dramatically increased number of transplants in the elderly MDS population in the United States. 25 A German multicenter trial (https://clinicaltrials.gov/show/NCT01404741) treats patients 55-70 years of age with higher-risk IPSS MDS, therapy-related MDS, or chronic myelomonocytic leukemia with azacitidine followed by biologic assignment to HCT or continued azacitidine. 26 These studies may provide more definitive evidence of the benefit of HCT in older patients with MDS and garner increasing awareness and application of this treatment modality for elderly patients with MDS.
